Business · 15/09/2022Updated: 10/17/2026 · 1 min read
FDA Withdraws Bacitracin for Injection from Sale Due to Safety Concerns
Summary
The US Food and Drug Administration has made the decision to remove bacitracin for injection, 10,000 units/vial and 50,000 units/vial, from the market due to concerns over its safety and effectiveness, and will no longer consider applications for abbreviated new drug applications for this product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →